Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG-801 Phase III Trial in Hyperkalemia
NCT04955678Phase 3Completed
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperkalemia comparing ZG-801 with Placebo (2 arms). Primary endpoint: Change in serum potassium value at 4 weeks. Started Aug 2021; status: completed.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT04955678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04955678.